Press Release on the audited (standalone and consolidated) Financial Results for the quarter and year ended March 31, 2026

Profit growth above 25%Exceptional itemResults View source PDF Explain this filing

KRSNAA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹550.00

prior close

₹622.55

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%-2.2% vs market

Healthcare Service Provider peers, median of 24sector-1.3%-0.1% vs sector

On the reaction day the stock moved 2.2 pts less than Nifty Microcap 250 and 0.1 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-7.9

10m

-9.7

15m

-8.8

30m

-8.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5+0.7-2.2-1.3-0.1

Next day

-1.8+0.7-2.5+1.3-3.1

+0.0+0.0-0.0+1.2-1.2

-1.7-1.1-0.6-1.3-0.4

-0.5+0.0-0.5-1.2+0.7

-1.7+0.3-1.9-0.8-0.9

+0.5+1.1-0.6-1.3+1.8

15d

-2.5+4.9-7.4+1.6-4.2

-1.8+5.3-7.1-0.1-1.7

-1.4+6.9-8.3-4.2+2.8

+1.9+11.9-10.0+0.8+1.1

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 24Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Krsnaa Diagnostics reported its highest ever Profit After Tax of ₹1,014 million in FY2026, a 31% growth over the prior year on a consolidated basis. Revenue stood at ₹7,728 million. The PAT figure includes a fair valuation gain of ₹221.75 million from investment in Apulki Healthcare Private Limited, which is a one-time exceptional item. Diluted EPS improved 31% to ₹30.88. Operating cash flows surged 64% to ₹1,431 million from ₹873 million, showing strong improvement in collections and working capital management. The retail diagnostics vertical achieved an 8x revenue jump within 12 months, expanding to 3,500 locations across 5 states. The Board recommended a final dividend of ₹2 per share.

Likely market impact

Strong performance with record PAT and 64% jump in operating cash flows is positive for shareholders, though the reported PAT growth is inflated by a one-time fair valuation gain of ₹221.75 million. Investors should note the underlying PAT growth excluding this exceptional item.